Research progress in anti-HCV therapeutic regimens without interferon
10.3969/j.issn.1001-5256.2016.01.037
- VernacularTitle:无干扰素抗HCV方案的研究进展
- Author:
Qiang LI
;
Yuxian HUANG
;
Liang CHEN
- Publication Type:Journal Article
- Keywords:
hepatitis C,chronic;
antiviral agents;
protease inhibitors;
review
- From:
Journal of Clinical Hepatology
2016;32(1):169-173
- CountryChina
- Language:Chinese
-
Abstract:
There are about 150 million people around the world with chronic hepatitis C virus (HCV)infection currently,of whom 20%will ultimately progress to cirrhosis and eventually die of end-stage liver disease and hepatocellular carcinoma.Interferon (IFN)has long been recognized as the cornerstone of the treatment of chronic hepatitis C because of its role in sustained virologic response and prevention of disease progression.However,it has limited efficacy and multiple adverse effects.In recent years,direct-acting antiviral agents (DAAs) have shown good efficacy.This review summarizes the recent advances in IFN-free anti-HCV therapeutic regimens based on DAAs.We believe that,with the emergence of DAAs,IFN-free therapies will develop rapidly and display better prospects.
